Verteporfin photodynamic therapy for the treatment of choroidal haemangioma associated with Sturge-Weber syndrome.

PURPOSE: Choroidal haemangiomas associated with Sturge Weber syndrome most commonly affect the posterior pole and consequently result in amblyopia. Treatment is often challenging but usually unwarranted unless there is visual deterioration caused by exudative or neovascular complications. The main objective is to demonstrate the effectivity of photodynamic therapy in this context.

DESIGN AND

METHODS

Retrospective analysis of prospectively collected data regarding verteporfin photodynamic therapy (PDT) in the treatment of patients with choroidal haemangiomas associated with Sturge Weber syndrome.

RESULTS

Six patients (4 male, 2 female) with a median age of 28 years (range, 23-67) had a mean tumour belly diameter of 12.2mm (range, 9-16.8). There was regression of the tumour in all cases, albeit after 3 treatments in a single case. The exudative retinal detachment resolved in 2 out of 3 patients. Visual outcome improved in 3 patients, remaining poor but stable in the other three, due to pre-existing amblyopia.

CONCLUSIONS

PDT is an effective and safe treatment for patients with choroidal haemangioma associated with Sturge-Weber syndrome.